Latest News

Thursday, May 26, 2016 | Clinical Trials, Acucela

Phase 2b/3 Clinical Trial of Acucela's Emixustat Does Not Meet Primary Endpoint

Acucela announced top-line results from the phase 2b/3 clinical trial (SEATTLE study) of the investigational visual cycle modulator emixustat hydrochloride (emixustat), according to a company news rel…

Read the full story

Wednesday, May 25, 2016 | Management/Leadership, Alphaeon

Robert Grant No Longer CEO of Alphaeon

Robert Grant is no longer CEO of Alphaeon, Eyewiretoday.com has learned. After 3 years at the helm of the lifestyle health care company, Mr. Grant is relinquishing the leadership role of the company h…

Read the full story

Wednesday, May 25, 2016 | Retina, Regeneron Pharmaceuticals

Regeneron Announces US Prescribing Information Clarification for Eylea (aflibercept) Injection

Regeneron Pharmaceuticals announced that the FDA has approved an update to the dosage and administration section of the Eylea (aflibercept) Injection US Prescribing Information for patients with neova…

Read the full story

Wednesday, May 25, 2016 | Medical Studies, American Academy of Ophthalmology

Zika Virus May Be Linked to More Eye Problems in Brazilian Babies with Microcephaly

Researchers studying babies with a Zika virus-related birth defect say they have found previously unreported eye problems possibly linked to the virus that could result in severe visual impairment, ac…

Read the full story

Tuesday, May 24, 2016 | Management/Leadership

Visiometrics Appoints New Vice President

Ophthalmic diagnostic instrument maker Visiometrics has appointed Nick Levandowsky Vice President, Global Marketing and North America Sales, according to a company news release. In his new role, Mr…

Read the full story

Tuesday, May 24, 2016 | Miscellaneous, Bausch+Lomb, Valeant

Valeant CEO Papa Calls B&L Division a 'Core Franchise'

Valeant Pharmaceuticals International Inc. would contemplate selling off some assets but sees Bausch & Lomb Inc.’s ophthalmic division as a “core franchise” it should hang on to,…

Read the full story

Tuesday, May 24, 2016 | Clinical Trials, Alimera Sciences

Majority of Chronic DME Patients Gain or Maintain Vision with Single Iluvien Injection Injection at 12 Months

Two real world data sources, revealed at the Royal College of Ophthalmologists (RCOphth) Annual Congress, show that the majority of chronic diabetic macular edema (DME) patients who received a single …

Read the full story

Tuesday, May 24, 2016 | Medical Studies, American Academy of Ophthalmology

Fireworks Eye Injuries Have More Than Doubled in Recent Years

Fireworks sales will start blazing across the country starting Memorial Day weekend, running through the Fourth of July. As retailers begin their promotions, the American Academy of Ophthalmology is s…

Read the full story

Tuesday, May 24, 2016 | Health Care

South Carolina Bans Remote Exams for Eyeglass Prescriptions

The South Carolina legislature has overridden a veto of Gov. Nikki Haley (R) to make South Carolina the 10th state to ban eyeglass prescriptions based solely on remote eye exams. This action spotlight…

Read the full story

Monday, May 23, 2016 | Miscellaneous, IRIDEX

Iridex Supports 'Eyes of Africa' Program

Iridex Corp. has announced the donation of an 810 nm OcuLight SLx to the Eyes of Africa Project in Malawi. The Iridex 810nm OcuLight SLx is a multifunctional laser that can be used to perform retinal …

Read the full story

Monday, May 23, 2016 | Medical Studies

Drug-Pricing Debate: Looking Past Big Pharma’s Nightmare Scenario

A comprehensive government crackdown on high drug prices isn’t likely soon. Still, investors shouldn’t let their guard down. Biotech and pharmaceutical stocks have struggled since last sum…

Read the full story

Monday, May 23, 2016 | Medical Studies

Multispot Panretinal Photocoagulation Spares Visual Fields Required For Driving Eligibility

Valon Lasers has announced that Valon multispot laser panretinal photocoagulation (PRP) in proliferative diabetic retinopathy spares visual fields required for driving eligibility, according to …

Read the full story

Friday, May 20, 2016 | Medical Studies

OCT Angiography Moves Beyond Ophthalmic Applications

A new imaging platform launched by Wasatch Photonics aims to widen the range of applications for high-resolution optical coherence tomography angiography, and enhance the versatility of the technique …

Read the full story

Friday, May 20, 2016 | Health Care

S.C. Senate and House Override Governor’s Veto of ‘Eye Care Consumer Protection Law’ Banning Online Eye Exams

The South Carolina House of Representatives voted to override Governor Nikki Haley’s May 16 veto of the "Eye Care Consumer Protection Law" (Bill No. 1016) which seeks to ban companies …

Read the full story

Thursday, May 19, 2016 | Medical Studies

Study: Visual Impairment and Blindness Prevalence in the US to Double by 2050

A study published by researchers at the University of Southern California (USC) Roski Eye Institute in JAMA Ophthalmology found that the US prevalence in visual impairment (VI) and blindness is expect…

Read the full story
Load More
 Stock Price  Change 
 Aerie Pharmaceuticals, Inc. $16.66  0.00% 
 Akorn, Inc. $30.40  0.00% 
 Alimera Sciences, Inc. $1.55  0.00% 
 Allergan $227.85  0.00% 
 Avalanche Biotechnologies $4.14  0.00% 
 Bayer $97.48  0.00% 
 Can-Fite Biopharma $2.70  0.00% 
 Carl Zeiss Meditec $33.76  0.48% 
 Cooper Companies, Inc. $164.62  0.00% 
 Eleven Biotherapeutics $1.09  0.00% 
 Escalon Medical Corp. $0.72  0.00% 
 Essilor International $128.75  0.00% 
 Glaukos $24.79  0.00% 
 Imprimis Pharmaceuticals, Inc. $3.98  0.00% 
 Inotek Pharmaceuticals $9.09  0.00% 
 InSite Vision, Inc. $0.35  0.00% 
 IRIDEX Corporation $13.96  0.00% 
 Johnson & Johnson $113.35  0.00% 
 Luxottica Group, S.p.A. $54.42  0.00% 
 Merck & Company, Inc. $56.57  0.00% 
 NicOx $10.96  0.60% 
 NovaBay Pharmaceuticals, Inc. $2.83  0.00% 
 Novartis AG Common Stock $79.90  0.00% 
 Ocular Therapeutix $11.88  0.00% 
 Ophthotech Corporation $50.75  0.00% 
 QLT $1.43  0.00% 
 Quantel $3.66  0.27% 
 Regeneron $394.49  0.00% 
 Roche $31.97  0.00% 
 Second Sight Medical Products $3.86  0.00% 
 Shire $191.78  0.00% 
 STAAR Surgical Company $5.62  0.00% 
 TearLab Corporation $0.79  0.00% 
 Thrombogenics $3.61  0.00% 
 Topcon Corporation $9.29  0.00% 
 TriVascular Technologies, Inc. $5.87  0.00% 
 Valeant Pharmaceuticals $27.12  0.00% 
 Xoma $0.71  0.00%